Candriam S.C.A. Hutchmed (China) LTD Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding HCM
# of Institutions
65Shares Held
6.88MCall Options Held
6.2KPut Options Held
1.1K-
Schroder Investment Management Group London, X02.92MShares$42.3 Million0.06% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.32MShares$19.2 Million0.04% of portfolio
-
State Street Corp Boston, MA350KShares$5.06 Million0.0% of portfolio
-
Aia Group LTD Hong Kong, K3315KShares$4.56 Million0.17% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny310KShares$4.49 Million0.0% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $2.5B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...